Recent Inlog Acquisition Provides Established Cellular Therapy Solution
DENVER, July 8 /PRNewswire-FirstCall/ -- Global Med Technologies(R), Inc. ("Global Med" or "the Company") (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, today announced the immediate release in the United States of EdgeCell(TM), a proven cellular therapy software solution for tissue banks, stem cell laboratories and cord blood banks. EdgeCell, with an installed base in Europe, will provide U.S. customers with an established Cellular Therapy product that has been meeting the needs of a variety of European customers.
EdgeCell is a state-of-the-art Cellular Therapy software solution for hospitals, surgery centers and health care facilities. EdgeCell fully tracks the procurement process including the medical history questionnaire; any required testing including specimen reception and infectious disease testing; product preparation including packaging, labeling and storage as well as crossmatching and distribution. Along with an extensive list of safety features, EdgeCell incorporates full traceability and generation of regulatory documentation.
The complex nature of tissue banks, stem cell laboratories and cord blood banks dictates that distinct business rules and parameters be tailored to each type of product. EdgeCell meets this need through its ability to configure and maintain distinct business rules and parameters for each type of product be it tissue (bone parts, whole bone, cells, valves, cornea, skin, and other tissues), stem cells or cord blood. Inlog has the ISO 9001:2000 and NSF/ISO 25051/12119 certification for EdgeCell and its other products assuring the highest level of quality regarding the design, testing and validation of the software, the documentation of the software and the quality of support and maintenance.
Raphael Bardonnet, M.D., Director of the BioBank in Paris, France, stated, "BioBank required a software solution that could meet our evolving needs as we develop new technologies for the preparation and processing of our biologics. We looked to Inlog, one of the European leaders in blood transfusion and medical software, for our tissue banking needs. For us, it was the logical choice because of Inlog's high quality standards and the ease with which EdgeCell can be configured for the multiple tissue types that we procure and the unique processes we use to prepare, test, store and distribute."
Dr. Bardonnet went on to state, "As our researchers continue to develop innovative methods to prepare our products, EdgeCell can be easily adapted, without custom software development, to fully track our new processes including equipment and ancillary products that were used. We have been very satisfied with the reliability and ease of use in the EdgeCell client server graphical software application."
Thomas F. Marcinek, President and COO of Global Med Technologies, stated, "We are very proud to offer EdgeCell for sale in the United States. When we made the announcement at our annual User Group meeting, our customers were very excited to hear about the imminent availability of a proven cellular therapy solution with an established customer base. EdgeCell is a product of Global Med's recent acquisition of Inlog, a leading provider of medical technology solutions with customers at 700 sites in 15 European, African and Middle Eastern countries."
Mr. Marcinek added, "We know the need for software solutions such as EdgeCell is rapidly increasing as more hospitals enter the emerging tissue transplantation market. With a global target market of more than 10,000 hospitals and surgical centers, we see EdgeCell as a growth platform that will greatly enhance our domestic and international expansion. We are confident in this product and its ability to provide the quality transplant management software our customers and potential customers have been seeking. As a forerunner in this essential technology, we are poised to satisfy the growing demand for proven biologic transplant management systems and to grow our global presence as a provider of quality healthcare software solutions."
About Global Med Technologies, Inc.
Global Med Technologies(R), Inc. is an international medical software company which develops regulated and non-regulated software products and services for the healthcare industry. As a leading provider of blood and laboratory software applications and services, Global Med's products are deployed in 20 countries and serve over 1,400 transfusion centers, blood banks and laboratories.
Global Med's U.S. division, Wyndgate Technologies(R), provides Vein-to-Vein(R) tracking through its Donor Doc(TM), SafeTrace(R), SafeTrace Tx(R) and ElDorado Donor(TM) software products. Each year, Wyndgate's products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply.
Global Med's European subsidiary, Inlog, SA, is a leading provider of donor center and transfusion management systems as well as cellular therapy software, laboratory information systems and quality assurance medical software systems internationally. Inlog's products include EdgeBlood**, EdgeTrack**, EdgeCell, EdgeLab and SAPA.
Global Med's U.S. subsidiary, PeopleMed(R), Inc., provides cost-effective customized software validation, consulting and compliance solutions to hospitals and donor centers.
For more information about Global Med's products and services, please call 800-996-3428 or visit http://www.globalmedtech.com, http://www.peoplemed.com, http://www.inlog.com and http://www.wyndgate.com.
**FDA 510(k) clearance required prior to sales in the U.S.
This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release.
|SOURCE Global Med Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved